Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

@article{Canale2017ImpactOT,
  title={Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.},
  author={Matteo Canale and Elisabetta Petracci and Angelo Delmonte and Elisa Chiadini and Claudio Dazzi and Maximilian Papi and Laura Capelli and Claudia Casanova and Nicoletta De Luigi and Marita Mariotti and Alessandro Gamboni and Rita Chiari and Chiara Bennati and Daniele Calistri and Vienna Ludovini and Lucio Crin{\`o} and Dino Amadori and Paola Ulivi},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 9},
  pages={2195-2202}
}
Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC).Experimental Design: 136 EGFR-mutated NSCLC patients receiving first-line TKIs were analyzed. TP53 mutations were evaluated in 123 patients in relation to disease control rate (DCR… CONTINUE READING